Madrigal Pharmaceuticals entered an exclusive global licensing agreement with China-based CSPC Pharmaceutical Group for SYH-2086, a preclinical oral small-molecule GLP-1 receptor agonist. The deal includes a $120 million upfront payment and potential milestone payments totaling up to $2 billion. Madrigal intends to develop SYH-2086 in combination with its fatty liver disease drug Rezdiffra to enhance therapeutic efficacy for metabolic-associated steatohepatitis (MASH). Clinical development is planned to commence in the first half of 2026, reflecting Madrigal's strategy to expand its metabolic disease pipeline.